Chemotherapy-induced nausea and vomiting: Contemporary approaches to optimal management

Supportive Care in Cancer

Volumn 18, Issue SUPPL. 1, 2010, Pages

  Grunberg, Steven ^d   Clark Snow, Rebecca A ^a   Koeller, Jim ^b,c  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d NONE

Author keywords

Chemotherapy induced nausea and vomiting; Cisplatin based therapy; Neurokinin 1 inhibitor; Selective 5 hydroxytrytamine 3

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; DIMENHYDRINATE; DIPHENHYDRAMINE; DROPERIDOL; FLUOROURACIL; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; NOSE SPRAY; ONDANSETRON; OPIATE; PALONOSETRON; PLACEBO; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

AGITATION; ANTICIPATORY NAUSEA AND VOMITING; ANTIEMETIC ACTIVITY; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DYSPHORIA; EDEMA; EMPATHY; ERYTHEMA; HAIR LOSS; HEALTH CARE PERSONNEL; HUMAN; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MOTION SICKNESS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; NOSE CONGESTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL BLOOD STEM CELL; POLYPHARMACY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RESTLESSNESS; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; STEM CELL TRANSPLANTATION; TESTIS CANCER; WHOLE BODY RADIATION; WORKLOAD;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; NAUSEA; NEOPLASMS; RISK FACTORS; VOMITING;

EID: 84755160773     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0807-z     Document Type: Conference Paper

References (56)

1. Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117-121
2. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schraq D (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25:5374-5380
3. Briesacher BA, Gurwitz JH, Soumerai SB (2007) Patients at-risk for cost-related medication nonadherence: a review of the literature. Gen Intern Med 22:864-871
4. Butow PN, Dunn SM, Tattersall MH, Jones QJ (1995) Computerbased interaction analysis of the cancer consultation. Br J Cancer 71:1115-1121
5. Cervený P, Bortlik M, Kubena A, Vicek J, Lakatos PL, Lukás M (2007) Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 13:1244-1249
6. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
7. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, van Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
8. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 160:2101-2107
9. Dix SP, Cord MK, Howard SJ, Coon JL, Belt RJ, Geller RB (1999) Safety and efficacy of a continuous infusion, patient controlled antiemetic pump to facilitate outpatient administration of high-dose chemotherapy. Bone Marrow Transplant 24:561-566
10. Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M (2005) Antiemetic therapy for multipleday chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13:112-116
11. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293-1300
12. 3 receptor antagonist. Cancer 98:2473-2482
13. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, Karlsen J, Giunchedi P (2006) Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 307:9-15
14. Gill D, Howell J (2008) Pharmacokinetics and bioavailability of transdermal granisetron after a 6-day application of three patch sizes, compared to 2 mg once-daily oral dose of granisetron for 5 days. Abstracts of the 2008 International MASCC/ISOO Symposium held in Houston, Texas, June 26-28, 2008. Abstract 01-006
15. Gorard DA (2006) Escalating polypharmacy. Q J Med 99:797-800
16. Gralla RJ, Itri L, Pisko SE, Squillante AE, Kelsen DP, Braun DW Jr, Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high-dose metrocloramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 305:905-909
17. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 12:2971-2994
18. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268
19. Grunberg SM, Gabrial N, Clark G (2007) Phase III trial of transdermal granisetron patch (Sancuso) compared to oral granisetron (OG) for chemotherapy-induced nausea and vomiting (CINV) after multi-day moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy. Abstracts of the 2007 International MASCC/ISOO Symposium held in St. Gallen, Switzerland, June 27-30, 2007. Abstract P-18.
20. Herrstedt J (2004) Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 3:231-248
21. Herrstedt J, Aapro MS, Smuth JF, Del Favero A (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6:204-214
22. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study. J Clin Oncol 21:4112-4119
23. Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M (2004) Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc Sci Med 59:1307-1313
24. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526-536
25. Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H (2007) Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer 48:330-332
26. Jordan K, Sippel C, Schmoll H-J (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143-1150
27. Kaufman DW, Kelly P, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337-344
28. Kimbell JS, Segal RA, Asgharian B, Wong BA, Schroeter JD, Southall JP, Dickens CJ, Brace G, Miller FJ (2007) Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med 20:59-74
29. Klocker N, Hanschke W, Toussaint S, Verse T (2001) Scopolamine nasal spray in motion sickness: a randomized, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci 13:227-232
30. Liau CT, Chu N-M, Liu H-E, Dueson R, Lien J, Chen J-S (2005) Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Support Care Cancer 13:277-286
31. Mardby A-C, Akerlind I, Jorgensen T (2007) Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 69:158-164
32. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega M (1990) The natural course of emesis after carboplatin treatment. Acta Oncol 29:593-595
33. McInnes FJ, O'Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, Stevens HN (2007) Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scinitigraphy. Eur J Pharm Sci 31:25-31
34. Morrow DG, Weiner M, Steinley D, Young J, Murray MD (2007) Patients' health literacy and experience with instructions influence preferences for heart failure medication instructions. J Aging Health 19:575-593
35. Murphy BA (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5:13-21
36. Newman SP, Steed KP, Hardy JG, Wilding IR, Hooper G, Sparrow RA (1994) The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques. J Pharm Pharmacol 46:657-660
37. Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16:771-778
38. Anonymous (2007) Oral mucosistis due to cancer treatments. La Revue Prescrire 27:286-288
39. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307-313
40. Pagano IS, Gotay CG (2005) Ethnic differential item functioning in the assessment of quality of life in cancer patients. Health Qual Life Outcomes 3:60
41. Penn RD, Kroin JS (1987) Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 66:181-185
42. Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monographs 32:32-39
43. Pirl WF, Temel JS, Billings A, Dahlin C, Jackson V, Prigerson HG, Greer J, Lynch TJ (2008) Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. Psychosomatics 49:218-224
44. Pollak KI, Arnold RM, Jeffreys AS, Alexander SC, Olsen MK, Abernethy AP, Sugg Skinner C, Rodriguez KL, Tulsky JA (2007) Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol 25:5748-5752
45. Repetto L (2003) Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1(suppl 2):18-24
46. Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology 21:946-953
47. Shih Y-CT Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678-685
48. Taylor JA, Winter L, Geyer LJ, Hawkins DS (2006) Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer 107:1400-1406
49. Valle AE, Wisniewski T, Isabel J, Vadillo F, Burke TA, Martinez Corona M (2006) Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Curr Med Res Opin 22:2403-2410
50. Wengstrom Y, Haggmark C (1998) Assessing nursing problems of importance for the development of nursing care in a radiation therapy department. Cancer Nurs 21:50-56
51. White PF, Tang J, Song D, Coleman JE, Wender RH, Oqunnaiike B, Sloninsky A, Kapu R, Shah M, Webb T (2007) Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. Anesth Analg 104:92-96
52. Wilkosz MF, Bogner RH (2003) Transdermal drug delivery. Part 1: current status. US Pharamcist 28:04 http://www.uspharmacist.com/index.asp?show= article&page=8-1061.htm. Accessed October 14, 2008
53. Winkeljohn DL (2007) Oral chemotherapy medications: the need for a nurse's touch. Clin J Oncol Nurs 11:793-796
54. Woo JS (2006) Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. Arch Pharm Res 30:778-784
55. Zaki NM, Mortada ND, Awad GAS, Abd El Hady SS (2006) Rapid-onset intranasal delivery of metoclopramide hydrochloride part II: safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm 327:97-103
56. Zarowitz BJ (2007) Fixed-dose combinations for improving medication adherence in assisted living environments. Geriatr Nurs 28:341-345